Growth Hormone Research Market

Hexarelin

A growth hormone secretagogue and ghrelin-receptor agonist that remains a familiar legacy name in GH-peptide stacks.

Growth HormoneGhrelin ReceptorSecretagogueResearch Market

Also appears in: Hormone

Price compare
11 tracked offers across 11 vendors · 3 dosages
Best trust-adjusted value: Peptide Sources · Light trust · $9.00/mg
From
$5.60/mg
Status
Research Market

This name primarily lives in the research market and should not be read like an approved pharmaceutical product.

Category
Growth Hormone

Primary lane: Growth Hormone. Also surfaces under Hormone for browsing and discovery.

Aliases
0

No major aliases are tracked for this profile yet.

Signal depth
Low

No FDA label signal · 0 trials · 289 PubMed results

Preclinical
Research evidence

Current evidence for Hexarelin is limited to laboratory or animal studies — there are no name-matched human trials with reported results. Any claims about effects in people are not yet backed by clinical data.

Hexarelin has no clinical trials that name it and 289 PubMed-indexed publications and is not FDA-approved. Current evidence is preclinical or mechanistic.

Human data
Lab / animal only
Trial quality
No human trials
Outcomes
No human trials
Replication
Multiple papers
Literature
High-impact
The Journal of Clinical Endocrinology & Metabolism · 504 citations Endocrine Activities of Ghrelin, a Natural Growth Hormone Secretagogue (GHS), in Humans: Comparison and Interactions with Hexarelin, a Nonnatural Peptidyl GHS, and GH-Releasing Hormone<sup>1</sup> The Journal of Clinical Endocrinology & Metabolism · 155 citations Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, after intravenous, subcutaneous, intranasal, and oral administration in man. Journal Article The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. Journal Article Hexarelin promotes the survival of retinal ganglion cells after optic nerve transection. Journal Article Identification of alexamorelin consumption biomarkers using human hepatocyte incubations and high-resolution mass spectrometry. Journal Article Pharmacological targeting of the hyper-inflammatory response to SARS-CoV-2-infected K18-hACE2 mice using a cluster of differentiation 36 receptor modulator.
Evidence history

Re-checked nightly against the registries — tracked since 2026-07-09. No band changes yet.

Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-07-13 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →

What hexarelin is

Hexarelin is a growth hormone secretagogue and ghrelin-receptor agonist that predates many of the newer GH-related peptide stacks now discussed online.

Why it matters

It belongs in the library because it is still a recognizable legacy name alongside compounds like GHRP-2, GHRP-6, and ipamorelin.

Regulatory context

Hexarelin is not FDA approved for routine consumer therapeutic use in the United States. It fits best in the research-market category.

Practical reading note

Hexarelin helps show the older side of the GH-secretagogue ecosystem, which is useful context when newer peptides get marketed as if they appeared from nowhere.